Flyer

International Journal of Drug Development and Research

  • ISSN: 0975-9344
  • Journal h-index: 51
  • Journal CiteScore: 46.50
  • Journal Impact Factor: 26.99
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • Scimago
  • Directory of Research Journal Indexing (DRJI)
  • OCLC- WorldCat
  • Publons
  • MIAR
  • University Grants Commission
  • Euro Pub
  • Google Scholar
  • J-Gate
  • SHERPA ROMEO
  • Secret Search Engine Labs
  • ResearchGate
  • International Committee of Medical Journal Editors (ICMJE)
Share This Page

Abstract

Positioning for Success in University-Industry Drug-Discovery Collaborations: Initiatives towards Effective Trans-Constituency Team Science

David R Janero

Despite entrenched differences between academia and the industrial sector, business models partnering universities and commercial entities to conduct preclinical drug-discovery team science are increasingly prevalent as attempts to boost and de-risk therapeutics invention. This dichotomy invites consideration of three high-level contextual elements that can help such trans-constituency alliances actualize their potential: an enabling operational profile as strategic roadmap; milestones supporting project progress and inviting improvement; and a critical mass of capable, engaged academic and industrial co-participants working across institutional boundaries and sharing risks and rewards. These elements bring many (in)tangible and often underappreciated benefits to a research-driven public-private discovery collaboration, e.g., underscoring its translational nature; acknowledging the important roles of vigilant self-evaluation and change; setting trust and quality expectations; establishing lines of communication and accountability; inviting knowledge cross-pollination; and avoiding project compromise by cross- purpose activities and personal/institutional self-interests. Although the inherently unpredictable nature of scientific progress and the heterogeneity of university-industry discovery collaborations preclude a universal success formula, pragmatic enablers discussed can help such alliances between academia and pharma/biotech traverse the rugged terrain at the science-business interface.